Advisory Research Inc Supernus Pharmaceuticals, Inc. Transaction History
Advisory Research Inc
- $548 Million
- Q4 2024
A detailed history of Advisory Research Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Advisory Research Inc holds 17,179 shares of SUPN stock, worth $554,538. This represents 0.11% of its overall portfolio holdings.
Number of Shares
17,179
Previous 17,097
0.48%
Holding current value
$554,538
Previous $533,000
16.51%
% of portfolio
0.11%
Previous 0.1%
Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$335 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$199 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$156 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$92.9 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$84.9 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.73B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...